Gastrointestinal stromal tumors are rare cancerous growths that develop in the walls of the digestive system, most often appearing in the stomach or small intestine, and while they may grow silently for years, early detection and proper treatment can significantly improve outcomes for those affected.

Epidemiology

Gastrointestinal stromal tumors, commonly known as GISTs, are the most common type of cancerous growth that develops from the supporting tissues of the digestive tract, yet they remain quite rare overall. In the United States, between 4,000 and 6,000 new cases are diagnosed each year. This translates to an age-adjusted yearly incidence of approximately 6.78 cases per million people.^[1][2][10]

The actual number of people affected by GISTs may be higher than reported because very small tumors, particularly those less than one centimeter in size, often don’t cause any symptoms and may never be detected during a person’s lifetime. Many of these tiny tumors remain dormant and never grow large enough to cause problems. Because they are so small and don’t appear in cancer registries, the true incidence of GISTs is difficult to determine and some estimates suggest it could be as high as 22 cases per million people annually.^[5][11]

GISTs can affect people at any age, but they are most commonly diagnosed in older adults. The median age at diagnosis ranges from 60 to 69 years, meaning that half of all patients are diagnosed before this age and half after. While adults of any age can develop GISTs, they are most predominant in those over 50 years old. The condition is extremely rare in children and young adults, accounting for less than 1% of all cases, and when it does occur in this age group, it is nearly always associated with an underlying genetic predisposition.^[1][8][11]

Globally, GISTs affect men and women with roughly equal frequency, though some studies have noted slightly higher rates in males. Geographic variations exist, with the highest prevalence observed in China (particularly Shanghai), Taiwan, Korea, and Norway. In the United States, there are notable differences in incidence rates among racial and ethnic groups. Black Americans have a higher rate at 13.7 cases per million, followed by Asian or Pacific Islander Americans at 11 per million, while White Americans have a lower rate of 6.5 cases per million.^[10][11]

Causes

The cause of most gastrointestinal stromal tumors is not fully understood, but scientists have made significant progress in identifying the genetic changes that lead to their development. GISTs are thought to begin in specialized nerve cells called interstitial cells of Cajal, which are found in the walls of the digestive organs. These cells act like pacemakers for the digestive system, sending signals to the muscles in the digestive tract wall that help move food and liquid through the body.^[1][7]

A GIST starts when these nerve cells in the digestive system develop changes in their DNA, the genetic material that carries instructions for how cells should function. These DNA changes, called mutations, cause the cells to grow and multiply uncontrollably. Instead of dying when they should, as normal cells do, these abnormal cells continue to accumulate and form a tumor.^[1]

About 80% of GIST cases are associated with a mutation in a gene called KIT. This gene provides instructions for making a receptor protein that sits on the surface of certain cells. When the KIT gene is mutated, the receptor protein it produces no longer needs its normal trigger to become activated. Instead, the protein stays constantly turned on, sending continuous signals that tell cells to grow and divide. This leads to uncontrolled cell growth and the formation of tumors.^[8][10]

Another 10% of GIST cases involve mutations in a gene called PDGFRA, which works in a similar way to KIT. Like KIT mutations, PDGFRA mutations cause receptor proteins to be constantly activated, leading to excessive cell growth. Less commonly, mutations in other genes, including SDHA, SDHB, SDHC, or SDHD, are involved in the development of GISTs. A small number of people with GISTs have mutations in other genes that researchers are still working to identify.^[8][10]

In most cases, GISTs occur sporadically, meaning the genetic mutations happen randomly during a person’s lifetime rather than being inherited from parents. There are no known lifestyle-related or environmental causes of GISTs, such as diet, smoking, or exposure to certain chemicals. This makes GISTs different from many other types of cancer where lifestyle factors play a significant role.^[10][22]

Risk Factors

While most gastrointestinal stromal tumors occur randomly without any identifiable cause, certain factors can increase a person’s risk of developing this condition. Understanding these risk factors can help doctors identify individuals who may need closer monitoring, though it’s important to note that having a risk factor doesn’t mean a person will definitely develop a GIST, and many people who develop GISTs have no known risk factors at all.^[1][10]

Age is one of the most significant risk factors for GISTs. The condition is most commonly diagnosed in people over 50 years old, with the majority of cases occurring in those between 60 and 70 years of age. While GISTs can technically develop at any age, they are very rare in children and young adults. When these younger age groups do develop GISTs, there is usually an underlying genetic condition involved.^[1][8]

Certain rare genetic syndromes significantly increase the risk of developing GISTs. One of these is familial GIST syndrome, an inherited condition that runs in families. People with this syndrome carry an abnormal KIT gene or, less commonly, an abnormal PDGFRA gene that they inherited from a parent. These individuals often develop GISTs at a younger age than the general population and may have multiple tumors rather than just one. However, this syndrome is extremely rare.^[2][8][22]

Neurofibromatosis type 1, also known as von Recklinghausen disease, is another genetic condition that increases GIST risk. This disorder is caused by a defect in the NF1 gene and can be either inherited from a parent or occur as a new mutation. People with neurofibromatosis type 1 are at increased risk for developing not only GISTs but also other types of tumors, particularly nerve sheath tumors called neurofibromas. Some individuals with this condition may develop multiple GISTs, often in the small intestine.^[7][9][22]

Carney-Stratakis syndrome is a rare genetic condition caused by mutations in one of the SDH genes. People with this syndrome typically develop GISTs at a young age, often in their teens or twenties. The tumors mainly occur in the stomach, and affected individuals often have more than one tumor. They are also prone to developing nerve tumors called paragangliomas. When GISTs occur together with paragangliomas, the condition is specifically referred to as Carney-Stratakis syndrome.^[7][8][22]

Another related condition is Carney triad, which involves the combination of GISTs, paragangliomas, and noncancerous lung tumors called pulmonary chondromas. This condition is also associated with SDH deficiency and tends to affect younger individuals. GISTs associated with SDH deficiency account for about 5 to 7% of all GIST cases and have different characteristics compared to those caused by KIT or PDGFRA mutations.^[8][10]

Symptoms

Many people with small gastrointestinal stromal tumors experience no symptoms at all, especially when the tumors are tiny and growing very slowly. In fact, small GISTs are often discovered by accident during imaging tests, endoscopy procedures, or surgeries performed for completely unrelated reasons. These incidental findings are quite common because small tumors may remain dormant for long periods without causing any noticeable problems.^[1][2][10]

As GISTs grow larger, they are more likely to cause symptoms. The specific symptoms a person experiences can vary depending on where the tumor is located in the digestive tract, how large it has grown, and how quickly it is expanding. Because GIST tumors have a rich blood supply and can become fragile as they grow, bleeding is one of the most common complications that leads to symptoms.^[2][11][22]

Bleeding from a GIST into the digestive tract can manifest in several ways. Some people may vomit blood, which can appear bright red or may resemble coffee grounds if the blood has been partially digested in the stomach. Others may notice their bowel movements have become black and tarry, a sign of bleeding from the stomach or small intestine. In cases of brisk bleeding into the large intestine, the stool may be visibly red with blood. Chronic, slower bleeding may not be immediately obvious but can lead to anemia, a condition where the body doesn’t have enough healthy red blood cells. People with anemia often feel extremely tired and weak.^[2][10][22]

Abdominal pain is another common symptom of GISTs. The pain may range from mild discomfort to severe cramping and can occur anywhere in the belly area. As tumors grow, they can create a noticeable lump or swelling in the abdomen that can sometimes be felt through the skin. Some people experience a sensation of fullness or bloating in their stomach, even after eating only a small amount of food. This early satiety can lead to unintentional weight loss over time.^[1][2][10]

Nausea and vomiting are frequent complaints among people with GISTs, particularly when tumors are located in the stomach or affect the movement of food through the digestive system. Loss of appetite is also common and can contribute to weight loss. For tumors located in the esophagus, difficulty swallowing may be the primary symptom. Some people may experience changes in their bowel habits, including diarrhea or constipation.^[1][10]

In rare cases, a GIST can rupture suddenly, which is a medical emergency requiring immediate attention. This acute rupture can cause severe abdominal pain and internal bleeding. GISTs can also grow large enough to cause obstruction in the digestive tract, preventing food from moving normally through the system. Both of these situations require urgent medical care.^[11][22]

Fatigue is a symptom that many people with GISTs experience, whether from anemia caused by chronic bleeding, from the tumor itself, or from the body’s response to having cancer. This fatigue can significantly impact daily activities and quality of life. It’s worth noting that all of these symptoms can be caused by many other conditions besides GISTs, which is why proper medical evaluation is essential if any of these symptoms persist.^[1][2]

Prevention

Unfortunately, at this time there is no known way to prevent gastrointestinal stromal tumors. Unlike many other types of cancer where lifestyle modifications can reduce risk, GISTs appear to develop from random genetic mutations that occur during a person’s lifetime. Because there are no identified lifestyle-related or environmental causes of GISTs, such as smoking, diet, alcohol consumption, or exposure to specific chemicals, there are no specific prevention strategies that have been proven effective.^[22][25]

The only known risk factors for GISTs are older age and specific inherited genetic syndromes, neither of which can be changed or prevented. This makes GIST fundamentally different from cancers like lung cancer, where avoiding tobacco can dramatically reduce risk, or skin cancer, where sun protection offers significant benefits. For people with inherited genetic conditions that increase GIST risk, such as familial GIST syndrome or neurofibromatosis type 1, there is currently no way to prevent the tumors from developing, though regular monitoring may help detect them early.^[22]

While prevention isn’t possible, early detection can improve outcomes. Because small GISTs often don’t cause symptoms and may grow slowly, some are found incidentally during medical imaging or procedures done for other reasons. For individuals with known genetic syndromes that increase GIST risk, doctors may recommend regular surveillance with imaging tests to catch tumors when they are still small and potentially more treatable. However, for the general population without known risk factors, there are no recommended screening programs specifically for GISTs.^[7][22]

That said, maintaining overall good health habits is always beneficial, even if they don’t specifically prevent GISTs. Eating a balanced diet, exercising regularly, maintaining a healthy weight, avoiding tobacco, and limiting alcohol consumption can help reduce the risk of many other types of cancer and chronic diseases. These habits also help ensure that if someone does develop a GIST or another health condition, they are in the best possible physical condition to tolerate treatment.^[22]

For people who have been successfully treated for a GIST, preventing recurrence often involves following their doctor’s recommendations for ongoing monitoring and, in some cases, continuing medication. Some patients may be prescribed adjuvant therapy after surgery, typically with a medication called imatinib (Gleevec), which can help reduce the risk of the tumor coming back. The decision to use adjuvant therapy depends on several factors, including the size of the original tumor, its location, and how quickly the tumor cells were dividing.^[2][12]

Pathophysiology

Understanding what happens in the body when a gastrointestinal stromal tumor develops requires looking at both the normal function of the digestive tract and how this process goes wrong in GIST. The digestive system relies on coordinated muscle contractions to move food and liquids through the esophagus, stomach, intestines, and other organs. This coordinated movement, called peristalsis, is controlled in part by specialized cells known as interstitial cells of Cajal, which act like electrical pacemakers for the digestive tract.^[1][4][7]

Interstitial cells of Cajal are located within the muscle wall of organs throughout the gastrointestinal tract. They send electrical signals to the smooth muscle cells in the digestive tract wall, telling them when to contract and relax. This creates the rhythmic waves of muscle contraction that push food along the digestive system. In healthy conditions, these cells carefully regulate their own growth and function through normal cell signaling pathways.^[4][7]

GISTs are thought to develop when interstitial cells of Cajal, or cells that would normally develop into these specialized cells, undergo genetic mutations. The most common mutations affect genes called KIT and PDGFRA. These genes provide instructions for making receptor proteins that sit on the surface of cells. In normal circumstances, these receptors only become activated when specific proteins, called ligands, bind to them, like a key fitting into a lock. Once activated, the receptors trigger a cascade of signals inside the cell that regulate important processes like cell growth, division, and survival.^[8][10]

When mutations occur in KIT or PDGFRA genes, the receptor proteins they produce no longer need ligands to become activated. Instead, these mutated receptors are constantly turned on, a state called constitutive activation. This means the receptors continuously send signals telling the cell to grow and divide, even when it shouldn’t. The cell loses its normal controls on growth and begins to multiply uncontrollably. Over time, these abnormal cells accumulate and form a tumor.^[8][10]

The location and growth pattern of GISTs affect how they impact the digestive system. Most GISTs, about 60 to 70%, develop in the stomach, while 20 to 25% occur in the small intestine. Smaller percentages are found in the colon, rectum, and esophagus. GISTs typically arise within the muscle wall of the digestive tract and can grow in different directions. Some form solid masses that grow inward into the digestive tract opening, while others grow outward into the abdominal cavity. Large tumors tend to form external masses attached to the outer aspect of the bowel wall.^[5][11]

As GISTs grow, they develop their own blood supply to nourish the rapidly dividing tumor cells. This rich blood supply makes the tumors vascular, meaning they contain many blood vessels. However, these blood vessels are often fragile and abnormal, which is why bleeding is such a common complication of GISTs. The tumor tissue itself can also become friable, or easily damaged, as it grows. When blood vessels in the tumor rupture, blood can leak into the gastrointestinal tract or the abdominal cavity.^[11][22]

The size of a GIST is one of the most important factors in determining its behavior and impact on the body. Small GISTs, particularly those less than 2 centimeters, often grow very slowly and may never cause problems. However, as tumors grow larger, they are more likely to become symptomatic. Large tumors can physically obstruct the passage of food through the digestive tract, press on surrounding organs, or rupture and bleed. The rate at which tumor cells divide, measured by the mitotic rate, is another crucial factor. Tumors with high mitotic rates, meaning many cells are actively dividing, tend to be more aggressive and more likely to spread to other parts of the body.^[11][12]

In some cases, GISTs can spread beyond their original location to other parts of the body, a process called metastasis. The most common site for GIST metastasis is the liver, though the tumors can also spread to the lining of the abdominal cavity (peritoneum) and, less commonly, to the lungs. Unlike many other cancers, GISTs rarely spread to lymph nodes. When GISTs metastasize, they maintain the same characteristics as the original tumor, including the same genetic mutations.^[11]

Different genetic mutations in GISTs can lead to different behaviors and responses to treatment. For example, GISTs with mutations in exon 11 of the KIT gene tend to be more sensitive to certain medications, while those with exon 9 mutations are less responsive. GISTs caused by certain PDGFRA mutations, particularly the D842V mutation, are often resistant to standard treatments. Understanding the specific molecular changes in a particular tumor helps doctors predict how aggressive it will be and which treatments are most likely to be effective.^[8][19]